PD-1 mAb
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for PD-1 mAb, covering 2018-11-16 to 2022-07-07. Get the full timeline:
Most recent: Clinical Trial Update: Recombinant Human Angioendostatin /PD-1 Mab Combined With First-line Chemotherapy in the Treatment of Driver Gene Negative Advanced NSCLC [Phase 2]